本帖最后由 老马 于 2012-1-13 21:20 编辑
/ e; K1 [1 y: U* R. T3 K
. x3 `1 K& N! ^" y8 v3 \% x爱必妥和阿瓦斯丁的比较
: ~4 E$ p, B; Y- _. p+ ?: R
# L9 j: U! J1 Q2 S2 C* X0 |, u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) w3 _. Q$ | V. M4 T% P
0 ]& A3 {3 P, A/ _; M5 z
1 Y0 X- l- i9 ~6 f- |4 p/ Y
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/. F N* b# j# N
==================================================5 [7 [; \3 S8 D5 L! g; z; |
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)) {- a( W1 a+ e7 H7 }7 \
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 F4 B% ?! {( \" K! qResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.# q0 _. L. @. t' T& V2 X* S" k0 _+ D
|